This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
This follows post #88 rather than contradicting it.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Picking up post #92: that is the part I would want checked first.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
Coming back to post #94, because the follow-up matters more than the original answer.
Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
I read post #100 twice before replying, because I had assumed the opposite.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
post #106 answers the question as asked. The question underneath it is different.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Worth separating two things that post #107 runs together.
Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.
This follows post #111 rather than contradicting it.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
On post #111 — agreed on the reasoning, with one qualification.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
post #115 answers the question as asked. The question underneath it is different.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.